Alpha Tau Medical Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
44.0%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$661.5Knext fiscal year
FY EPS (est.)
-$0.88next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Liquidity Balance Quarterly80.2MTarget: Maintain sufficient runway for clinical trials
REGAIN Trial Enrollment Progress Monthly1.0
IMPACT Trial Planned Enrollment Quarterly
Watch Items
- ReSTART Pivotal Skin Cancer Trial Top-line DataTrigger: Data readout expected around the end of 2026Action: Prepare FDA Modular PMA submission toward year-end 2026
- Tolmar Strategic Collaboration MilestonesAction: Initiate clinical development of Alpha DaRT for prostate cancer in the U.S.
Research as of 19 Jun 2026